• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项关于静脉注射阿齐美克治疗人类癌症的I期研究。

A phase I study of intravenous azimexon therapy in human cancer.

作者信息

Patt Y Z, Hersh E M, Reuben J, Claghorn L, Mavligit G

出版信息

J Biol Response Mod. 1986 Aug;5(4):313-8.

PMID:2874196
Abstract

Azimexon, a synthetic derivative of the 2-cyanaziridines, was given intravenously daily for 5 days to 19 cancer patients in a Phase I trial designed to determine the drug's tolerable dose, toxicity, and effects on immune and nonimmune host defense parameters. No myelosuppression, neurologic, renal, hepatic, or gastrointestinal toxicities could be detected. The only toxic side effect observed after 5 days of intravenous azimexon was a self-limiting dose-dependent hemolysis. Absolute lymphocyte count (ALC) increased from a pretreatment value of 0.96 X 10(3)/microliter to 1.56 X 10(3)/microliter on day 21 (p less than 0.05). This increase was induced primarily by the less hemolytic 200-250 mg/m2 doses of azimexon. Among 12 patients given this lower dosage. ALC increased from an average initial value of 0.90 X 10(3)/microliter to 1.86 X 10(3)/microliter on day 21 (p less than 0.01). Absolute number of OKT3+ cells increased from 0.524 to 0.914 X 10(3)/microliter (p less than 0.05) with lower drug doses. The mean absolute number of OKT4+ cells increased from 0.294 on day 0 to 0.574 X 10(3)/microliter on day 21 (p less than 0.05), and the number of OKT8+ cells increased from 0.202 to 0.388 X 10(3)/microliter, with no significant changes in helper/suppressor ratio. Significant increases in mitogenic responses to phytohemagglutinin (PHA) [from 13.4 to 35.7 X 10(3) net cpm (p less than 0.05)] and to concanavalin A (con A) [from 6.4 to 25.6 X 10(3) net cpm (p less than 0.05)] were also observed with higher drug doses. Azimexon may have a role in managing cancer-associated dysregulation of the immune response.

摘要

氮咪克松是2-氰基氮丙啶的一种合成衍生物,在一项I期试验中,对19名癌症患者每日静脉给药,持续5天,该试验旨在确定药物的耐受剂量、毒性以及对免疫和非免疫宿主防御参数的影响。未检测到骨髓抑制、神经、肾脏、肝脏或胃肠道毒性。静脉注射氮咪克松5天后观察到的唯一毒性副作用是一种自限性的剂量依赖性溶血。绝对淋巴细胞计数(ALC)从预处理值0.96×10³/微升增加到第21天的1.56×10³/微升(p<0.05)。这种增加主要是由溶血作用较小的200 - 250mg/m²剂量的氮咪克松引起的。在接受较低剂量的12名患者中,ALC从平均初始值0.90×10³/微升增加到第21天的1.86×10³/微升(p<0.01)。较低药物剂量时,OKT3⁺细胞的绝对数量从0.524增加到0.914×10³/微升(p<0.05)。OKT4⁺细胞的平均绝对数量从第0天的0.294增加到第21天的0.574×10³/微升(p<0.05),OKT8⁺细胞数量从0.202增加到0.388×10³/微升,辅助/抑制比例无显著变化。较高药物剂量时,对植物血凝素(PHA)[从13.4增加到35.7×10³净cpm(p<0.05)]和刀豆球蛋白A(Con A)[从6.4增加到25.6×10³净cpm(p<0.05)]的促有丝分裂反应也有显著增加。氮咪克松可能在控制癌症相关的免疫反应失调中发挥作用。

相似文献

1
A phase I study of intravenous azimexon therapy in human cancer.一项关于静脉注射阿齐美克治疗人类癌症的I期研究。
J Biol Response Mod. 1986 Aug;5(4):313-8.
2
Effect of azimexon therapy on host defense parameters and disease-associated symptoms in the acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC).阿齐美克松疗法对获得性免疫缺陷综合征(艾滋病)和艾滋病相关综合征(ARC)患者宿主防御参数及疾病相关症状的影响。
AIDS Res. 1986 Summer;2(3):191-209. doi: 10.1089/aid.1.1986.2.191.
3
Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
Cancer Res. 1984 Feb;44(2):831-5.
4
Modulation in vitro of immune parameters in homosexual males with the preclinical complex of symptoms related to acquired immune deficiency syndrome by azimexon.阿齐美克对患有与获得性免疫缺陷综合征相关的临床前症状复合体的同性恋男性免疫参数的体外调节作用。
J Biol Response Mod. 1986 Jun;5(3):263-9.
5
[Biological effects of leakadin].
Vopr Onkol. 1988;34(2):192-6.
6
Phase I clinical evaluation of diaziquone in childhood cancer.
Cancer Treat Rep. 1985 Mar;69(3):323-7.
7
Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.重组白细胞介素-2与环磷酰胺的I期试验:长期给予重组白细胞介素-2增强细胞免疫和T细胞促有丝分裂反应。
J Biol Response Mod. 1988 Oct;7(5):457-72.
8
Phase I study of aziridinylbenzoquinone (NSC 182986).氮丙啶基苯醌(NSC 182986)的I期研究。
Cancer Clin Trials. 1981 Winter;4(4):459-63.
9
Immunorestoration of anergic cancer patients by azimexon.用阿齐美克恢复无反应性癌症患者的免疫功能。
Recent Results Cancer Res. 1980;75:47-52. doi: 10.1007/978-3-642-81491-4_8.
10
A pilot clinical trial of the toxicity and immunorestorative effects of T cell reconstituting factor (SR 270258) in immunosuppressed cancer patients.T细胞重建因子(SR 270258)对免疫抑制癌症患者毒性及免疫恢复作用的一项临床试验试点研究。
J Biol Response Mod. 1987 Feb;6(1):56-68.

引用本文的文献

1
Biological response modifiers and infectious diseases: actual and potential therapeutic agents.生物反应调节剂与传染病:实际与潜在的治疗药物。
Int J Antimicrob Agents. 1994;3(4):223-43. doi: 10.1016/0924-8579(94)90050-7.